Can Payers Trust Our Data?

The potential for real-world data to be used on a mass scale to demonstrate the effectiveness and value of medicines is great, promising benefits for all parties including better health outcomes and lower premiums for patients and higher prices for those selling the most effective treatments.Yet, while the use of real-world evidence is growing, a major impediment to its broader and faster adoption is the potential trust gap. After all, how can payers be sure that pharma ’s data tell a true and accurate story about patient outcomes?Payers are increasingly questioning the data they are provided with, says Michelle Hoiseth, Corporate VP at PAREXEL International, asking providers on what basis it is trustworthy and suitable.In order to meet the test of trustworthiness, we need to evaluate contradictions or conflicts in the data, whether the data are collected with integrity, the timing and the context of the original data collection, whether it is possible to change the data between its origin and the source being used for the analysis, whether data are coming from clinician sources or other sources, if data used are in unstructured fields and, if so, how they were extracted.“All those kinds of variables come into play,” says Hoiseth.There are several reasons for their lack of faith in the analysis from pharma companies not least among them is the payers ’ perception that there is a gap between what’s being reported and what’s being withheld when reporting a result, s...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news